{"product_id":"body-pharm-cjc-1295-with-dac-2-vial","title":"Bodypharm CJC 1295 with DAC 2 Vial","description":"\u003cp\u003eBody Pharm CJC-1295 with DAC 2mg is a lyophilised research peptide vial for in vitro investigation of GHRH analogue activity. The DAC (Drug Affinity Complex) modification extends the half-life to a commonly cited 6–8 days versus a sub-30-minute window for the non-DAC variant. This happens because the maleimidopropionic acid linker binds covalently to circulating serum albumin and protects the peptide from enzymatic cleavage. The live ZAR price is shown in the buy box at the top of this page.\u003c\/p\u003e\n\u003ch2 id=\"key-takeaways\"\u003eKey Takeaways\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCJC-1295 with DAC extends half-life to ~6–8 days through covalent albumin binding, versus sub-30 minutes for non-DAC variants\u003c\/li\u003e\n\u003cli\u003eThe 6–8 day figure originates from Teichman et al. (2006); no newer primary pharmacokinetic data has been published\u003c\/li\u003e\n\u003cli\u003eBody Pharm supplies the peptide as a 2 mg lyophilised vial\u003c\/li\u003e\n\u003cli\u003eRequest a batch-specific Certificate of Analysis before use; purity specifications are not independently verifiable from available sources\u003c\/li\u003e\n\u003cli\u003eStorage requires 2–8 °C protection from light; cold-chain handling during South African summer delivery is critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"what-is-body-pharm-cjc-1295-with-dac-2mg\"\u003eWhat Is Body Pharm CJC-1295 with DAC 2mg?\u003c\/h2\u003e\n\u003cp\u003eBody Pharm CJC-1295 with DAC 2mg is a synthetic 30-amino-acid GHRH analogue (DAC:GRF) supplied as a 2 mg lyophilised powder for in vitro laboratory research. The Drug Affinity Complex (DAC) is a maleimidopropionic acid linker that binds covalently to circulating serum albumin, protecting the peptide from dipeptidyl peptidase-IV cleavage and extending the cited half-life to roughly 6–8 days. The non-DAC modified GRF (1-29) form clears within sub-30 minutes.\u003c\/p\u003e\n\u003cp\u003eConjuChem developed the DAC conjugation chemistry in the early 2000s. Teichman et al. (2006) characterised the resulting long-acting GHRH activity in the pharmacokinetic work that the 6–8 day figure traces back to. No post-2006 primary PK replication was located in the current source set. The half-life value should be treated as 2006-era data pending newer literature.\u003c\/p\u003e\n\u003cp\u003eBody Pharm distributes the peptide in a single-vial 2 mg format. A manufacturer Certificate of Analysis and stated purity specification could not be verified from the available sources. Request these documents from the seller before order release.\u003c\/p\u003e\n\u003ch3\u003eQuick product definition\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemical class\u003c\/td\u003e\n\u003ctd\u003eGHRH analogue \/ growth hormone secretagogue (DAC:GRF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModification\u003c\/td\u003e\n\u003ctd\u003eDrug Affinity Complex — covalent albumin binding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003e2 mg lyophilised powder, single vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCited half-life\u003c\/td\u003e\n\u003ctd\u003e~6–8 days (Teichman et al., 2006)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClassification\u003c\/td\u003e\n\u003ctd\u003eResearch chemical, in vitro use only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2 id=\"cjc-1295-with-dac-vs-without-dac\"\u003eCJC-1295 with DAC vs. Without DAC\u003c\/h2\u003e\n\u003cp\u003eThe core procurement decision comes down to dosing cadence. DAC binds covalently to serum albumin and extends activity to roughly 6–8 days. The non-DAC Modified GRF (1-29) form clears within minutes and requires multiple administrations per research day because it lacks the albumin-binding modification.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eCJC-1295 with DAC\u003c\/th\u003e\n\u003cth\u003eCJC-1295 without DAC\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemical name\u003c\/td\u003e\n\u003ctd\u003eDAC:GRF (drug affinity complex GRF analogue)\u003c\/td\u003e\n\u003ctd\u003eModified GRF (1-29)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlso known as\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 DAC, long-acting GHRH\u003c\/td\u003e\n\u003ctd\u003eMod GRF 1-29, CJC-1295 no DAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCited half-life\u003c\/td\u003e\n\u003ctd\u003e~6–8 days (Teichman et al., 2006)\u003c\/td\u003e\n\u003ctd\u003eSub-30-minute plasma clearance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical research dosing frequency\u003c\/td\u003e\n\u003ctd\u003eOnce weekly or twice weekly\u003c\/td\u003e\n\u003ctd\u003eMultiple times per 24 h cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlbumin binding\u003c\/td\u003e\n\u003ctd\u003eCovalent via maleimidopropionic acid linker\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary research application\u003c\/td\u003e\n\u003ctd\u003eSustained GHRH receptor activation; chronic-exposure models\u003c\/td\u003e\n\u003ctd\u003ePulsatile GHRH studies mimicking endogenous release\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBody Pharm vial format\u003c\/td\u003e\n\u003ctd\u003e2 mg lyophilised, single vial\u003c\/td\u003e\n\u003ctd\u003e2 mg lyophilised, single vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Delinquent","offers":[{"title":"Default Title","offer_id":47653899501705,"sku":null,"price":460.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0743\/0438\/9257\/files\/bodypharmcjcvial.jpg?v=1784385959","url":"https:\/\/www.delinquent.co.za\/products\/body-pharm-cjc-1295-with-dac-2-vial","provider":"Delinquent","version":"1.0","type":"link"}